Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Nanobiotix ( (NBTX) ) just unveiled an announcement.
On May 15, 2025, Nanobiotix disclosed transactions by persons with managerial responsibilities in compliance with the EU Market Abuse Regulation. This notification, dated May 12, 2025, involved the acquisition of shares on Euronext Paris, reflecting ongoing strategic financial activities within the company.
The most recent analyst rating on (NBTX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
The overall stock score of 43 reflects Nanobiotix’s substantial financial challenges, including declining revenues, negative profitability, and a high leverage ratio. While the strategic partnership with JNJ offers potential future milestones and an extended cash runway, current financial performance and valuation metrics remain under significant pressure. Technical indicators show some positive momentum, but overall stock performance is hindered by underlying financial instability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix is a biotechnology company focused on developing innovative nanomedicine solutions. The company specializes in creating products that enhance radiotherapy treatments for cancer patients, aiming to improve therapeutic outcomes and patient quality of life.
Average Trading Volume: 12,374
Technical Sentiment Signal: Sell
Current Market Cap: $177.5M
For a thorough assessment of NBTX stock, go to TipRanks’ Stock Analysis page.